• Lexaria Bioscience has developed a patented technology that improves the bioavailability of pharmaceuticals and therapeutics in part by bypassing first-pass-liver processing
• Lexaria’s patented DehydraTECH (TM) technology is undergoing human clinical trials this year to determine its effectiveness in making cannabidiol (“CBD”) effective as a means of reducing blood pressure for high blood pressure patients
• The initial results of the first human clinical study showed the DehydraTECH-CBD compound was well tolerated by patients without troubling side effects and that the compound outperformed generic CBD controls
• Just-released initial (partial) results regarding the compound’s second human clinical trial show that a three-dose regimen was effective in reducing systolic pressure, mean arterial pressure and diastolic pressure as compared with a placebo when monitored for 24 hours

Technology innovator Lexaria Bioscience (NASDAQ: LEXX) is celebrating the initial (partial) results from its human clinical trial pitting its patented flagship platform DehydraTECH (TM), in combination with cannabidiol (“CBD”), against a placebo to measure how blood pressure patients respond to Lexaria’s patented technology. Lexaria’s HYPER-H21-2 human clinical study follows on the heels of initial clinical testing that showed DehydraTECH-CBD produced a reduction in blood pressure in both male and female volunteers and outperformed generic CBD controls in a single-dose regimen studied over the course of three hours (https://ibn.fm/HXctx). The second human clinical study assessed the efficacy of the DehydraTECH-CBD compound in a three-dose schedule over the first half of a 24-hour ambulatory monitoring period. The trial results showed patients who received DehydraTECH-CBD experienced a much greater trending decrease in systolic pressure, mean arterial pressure and diastolic pressure than the placebo during the course of the assessment, according to a Sept. 7 company news release (https://ibn.fm/ZzDjt). Lexaria is pursuing the validation of DehydraTECH-CBD in part because of a market need the company perceives for treating high blood pressure (hypertension), which is a key risk factor for both heart disease and stroke — the leading causes of death experienced by adult populations around the world, including in the United States. High blood pressure, as manifest in systolic pressure, mean arterial pressure and diastolic pressure, is a significant contributing factor to heart attack, stroke and other health threats involving the body’s organs. Lexaria cites other studies that have demonstrated that lowering systolic pressure or diastolic pressure by determined amounts reduced the incidence of coronary artery disease events, both fatal and nonfatal, by double-digit percentages. “Over the initial 24 hours, Lexaria’s 2021 hypertension program is now delivering blood pressure reduction results competitive with — and in some cases even superior to — established oral pharmaceutical hypertension drugs,” CEO Chris Bunka stated in the news release. “DehydraTECH-CBD demonstrated a sustained and augmented effect upon blood pressure attenuation throughout the day, indicating effectiveness of the repeat dosing treatment schedule used in this study.” As documented during the first DehydraTECH-CBD human clinical study, the substance was well tolerated by all of the patients without reports of serious adverse events or side effects, which could help eliminate risks incurred when heart patients stop taking their medications because of discomfort over unwanted effects. Lexaria is now awaiting the complete results on both DehydraTECH-CBD blood pressure human clinical studies, but has already affirmed that it will conduct a third clinical trial later this year related to (pulmonary) hypertension therapies and plans to add a fourth hypertension study that will monitor a larger population of hypertension patients during the course of at least four weeks to establish longer-term performance and tolerability, and to measure inflammatory and oxidative markers also. According to the World Health Organization (“WHO”), an estimated 1.28 billion people have high blood pressure, demonstrating the scale of the potential pharmaceutical market (https://ibn.fm/yFs8J). Transparency Market Research analysts estimate the annual revenues for the hypertension solutions market have reached $28 billion per year and will continue to grow (https://ibn.fm/1xesE). DehydraTECH is designed as a patented technology that improves the bioavailability of pharmaceuticals and therapeutic substances when orally ingested.  Testing has established DehydraTECH’s ability to transform the substances without defeating their effectiveness or creating new molecular entities (“NME”) which are generally subjected to more involved regulatory examination and approval processes than non-NMEs. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• So far in 2021, Tryp’s innovations have allowed it to position itself as a first-mover in the psychedelics space
• The company has announced completion of psychotherapy training for the upcoming phase 2a clinical trials for specific overeating disorders
• Tryp has also been keen on collaborating and partnering with key players in the industry, such as Calvert Labs and Gad Consulting services, the University of Michigan, and the University of Florida
• The company also understands the value of proper leadership and, so far in 2021, it has made strategic appointments to its board of directors

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is a pharmaceutical company that has remained focused on developing clinical-stage compounds for diseases with high unmet medical needs. Whereas its focus is on achieving this end through accelerated regulatory pathways, the company also understands the value of innovation, forging the right partnerships, and having exemplary leadership. So far, in 2021, Tryp has made some significant strides from an innovation standpoint, ultimately positioning itself as a first-mover in the psychedelics space.  Its lead drug candidate, TRP-8802, has proven to be promising in treating fibromyalgia (https://ibn.fm/c0oqI). The company believes that psilocybin, a critical component in its drug formulations, can be used more effective in unmet medical needs beyond mental health, and continues to explore that. Tryp has also just announced having completed psychotherapy training and plans to initiate the upcoming phase 2a clinical trial. This trial will utilize synthetic psilocybin in combination with psychotherapy for the treatment of specific overeating disorders. The company announced that the study will be conducted at the University of Florida (“UF”) and will aim at determining the safety and efficacy of psilocybin on hyperphagia (https://ibn.fm/M3hw1). It is a tremendous milestone for Tryp and an indication of its commitment to innovate and find solutions to medical conditions that have not had tangible and reliable treatments. Tryp has not shied away from collaborating and partnering with other players within the industry. In August, Tryp announced its partnership with Calvert Labs and Gad Consulting Services in a move that would facilitate the trial design and execution of the phase 2b clinical trials (https://ibn.fm/cHWZo). Tryp also announced the appointment of Dr. Dan Clauw to its Scientific Advisory Board on the heels of a collaboration with the Chronic Pain & Fatigue Research Center at the University of Michigan Medical School for the Fibromyalgia phase 2a clinical trial earlier in the year, a critical move for the company. The initiation of clinical trials is an integral step within Tryp’s strategic initiatives in it’s commitment to utilizing the FDA’s 505(b)(2) regulatory pathway, and available third-party preclinical data to shorten the approval timelines and lower the overall cost of development programs (https://ibn.fm/hYjOP). Experienced drug development leadership is also a fundamental aspect of Tryp’s operations. The company’s Chief Executive Officer (“CEO”), Mr. Greg McKee, has continued to successfully Tryp as a pioneer in the psychedelics space. In 2021 alone, the company has brought Mr. McKee onto the management team and made strategic board and advisory appointments, bringing key individuals such as Robin Carhart-Harris and Dennis Langer to help steer the company towards achieving its overall goal (https://ibn.fm/5o0DL). So far, Tryp has managed to have an executive and advisory team that has decades of experience working in leadership positions within critical organizations in the pharmaceutical space, such as Myriad Genetics, Syntex, Dow Chemical, Jubilant, Unigene Laboratories, and Genzyme (https://ibn.fm/VPy1Y).Together, these leaders help push Tryp’s agenda and offer solutions to issues with high unmet medical needs. 2021 has been an excellent year for Tryp, as the company has made incredible strides to further its mission. It is a testament to what can be achieved once a company has the right leadership, forges the right partnerships, and continues to innovate with its products and services. For more information, visit the company’s website at www.TrypTherapeutics.com. NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

• Through HealthTab, its flagship offering, Avricore turns pharmacies into community diagnostic centers by providing a turnkey point-of-care testing platform
• HealthTab is a multilayered operational ecosystem that provides endless possibilities, from lab-accurate tests to immediate results uploaded automatically on a web-based platform
• It enables patients to review the results on the spot with the pharmacist, allowing pharmacists to take on a more significant role in primary health services
• HealthTab ultimately aims to improve the quality of life for patients living with chronic illnesses

A recent McKinsey article observed that consumers deeply care about wellness now more than ever; this interest is growing by the day (https://ibn.fm/yy5hL). It defined wellness as encompassing better health, better fitness, better nutrition, better appearance, better sleep, and better mindfulness. McKinsey notes that better health, which is perhaps the most traditional category associated with wellness, “extends beyond medicine and supplements to include (consumer) medical devices, telemedicine, and remote healthcare services, as well as personal health trackers.” The article further states that in pursuit of better health, consumers are increasingly taking their health into their own hands, as seen through a rise in the reliance on, among others, devices that help them monitor their own health and symptoms between doctor’s appointments. The better health dimension is particularly important for companies such as Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF), a pharmacy services innovator. AVCR is leveraging such consumer health trends along with technological advancements to provide direct access to lab-accurate tests that measure and monitor conditions such as heart disease and diabetes. Through its flagship offering and wholly owned subsidiary, HealthTab(TM), the company turns pharmacies into community diagnostic centers by providing a turnkey point-of-care testing platform. HealthTab achieves this through a multilayered operational ecosystem that offers endless possibilities within a single platform, which first prompts the patient to create an account before using it. HealthTab utilizes the laboratory-accurate analyzers – Abbott’s Afinion 2(TM) and ID Now, as well as I-STAT – to provide valuable point-of-care screening at community pharmacies for various diseases and conditions, including diabetes, heart disease, kidney function, respiratory syncytial virus (“RSV”), influenza A and B, and Strep. Once a patient visits a pharmacy that offers HealthTab, they provide a tiny sample with a simple finger prick or swap. Currently, the platform tests and tracks a total of 23 biomarkers (https://ibn.fm/Go2Bu). The platform, which brings these analyzers into a single, secure, cloud-based network, automatically uploads each patient’s results to their respective health dashboard, meaning the patients can access their results on the spot, as well as review them with the pharmacist. With the insights contained in the results, patients can then take steps to a healthier future with the help of the pharmacist and doctor. In so doing, the HealthTab platform enables pharmacists to take on a greater role in primary health services and recent comments by a Mississauga, Ontario-based pharmacist Mohamed Adel Elsabakhawi, attest to this. On June 3, Avricore announced the rollout of a pilot program in which patients would have access to HealthTab and its testing and monitoring capabilities at select Shoppers Drug Mart locations. It then conducted an initial trial of the platform in an Ontario, Canada Shopper Drug Mart (https://ibn.fm/OBVRX). It was during this week-and-a-half trial period that Mohamed, who is also the Ontario store’s associate owner and first pharmacist to operate the platform, interacted with it. “I’m so excited to have HealthTab in my store because I believe this is going to demonstrate a new and better way to do pharmacy practice,” Mohamed had said (https://ibn.fm/mP8Yc). “This is really profound because having access to lab-accurate results at our fingertips means we can better help family physicians by conducting regular follow up using advanced diagnostics with our diabetic and cardiovascular patients more effectively.” In addition to enabling pharmacists to take on a more significant role in primary health services, HealthTab is capitalizing on the burgeoning point-of-care testing market expected to grow from an estimated $43.49 billion in 2021 to $81.37 billion in 2028, representing a 9.4% CAGR during the forecast period (https://ibn.fm/QTrSh). Nonetheless, Avricore ultimately aims to improve the quality of life for patients living with chronic illnesses. For more information, visit the company’s website at www.AvricoreHealth.com. NOTE TO INVESTORS: The latest news and updates relating to AVCRF are available in the company’s newsroom at https://ibn.fm/AVCRF

• The $6 million investment round was led by Crawford Hoying, a real estate holding company with more than $1.3 billion of mixed-use, multifamily, office, and retail properties
• The company is taking advantage of the new wave of investment opportunities in the emerging industry Airbnb has created
• Equity in reAlpha properties can be purchased for as little as $2,500 and handled much like buying stock in a company. Investors are matched with like-minded backers to cover the down payment on properties

reAlpha, often referred to as the Robinhood of Airbnb investments, recently announced that it has closed on a $6 million investment round. The lead investor of the round was real estate holding company Crawford Hoying, which has developed more than $1.3 billion of mixed-use, multifamily, office and retail properties. The new funding that reAlpha has received is set to accelerate the company’s growth, including its innovative short-term rental investment platform, data science function, and engineering capabilities. Proceeds will also be used to expand reAlpha’s geographical presence, operations, and member network (https://ibn.fm/xWiVQ). “reAlpha enables superior alpha yield by investing in short-term rental properties. We have simplified the entire process of investing and managing these properties using advanced technologies. This allows ‘Mainstreet’ investors to access the real estate investment market like never before,” said reAlpha CEO Giri Devanur. The founder of Crawford Hoying, Brent Crawford, called reAlpha’s proprietary technology a paradigm shift for the short-term rental investment market. “The proprietary technology developed to identify, acquire, and market properties with lower risk is a big leap. We strongly believe in the team’s conviction and vision to scale this into a leader in this space,” he said. Based on statements by reAlpha, a new wave of investment opportunities in the real estate industry is emerging, spurred by the heightened desire for short-term rentals and private accommodations which have only been accelerated post-pandemic. reAlpha’s model allows consumers to benefit from the superior returns of short-term rental income and the increase in property value through renovations and market appreciation conditions. Investors can invest in these short-term rental and vacation homes through the company’s platform and partner broker-dealer site, democratizing the market’s access. For an investment of as little as $2,500, first through the reAlpha app and then connected through to a broker dealer site, investors can purchase equity in a specific reAlpha property, much like buying stock in a company. The company matches members with other like-minded backers to form a syndicate, together covering a down payment on the property that has been selected. Most investment properties require a 25 percent down payment, but with reAlpha, that reduces to 10 percent because of the relationships the company has developed and nurtured with lenders. The company handles all property management functions and believes that short-term rentals are no longer just for transactional purposes. reAlpha reimagines the entire guest experience end-to-end, making sure that reAlphaHouse is the ultimate on-demand rental property. Targeting specific markets across the globe, reAlpha’s preference is to purchase 100 to 500 of these short-term rental properties in each market. When acquiring the properties, reAlpha uses its artificial intelligence technology “reAlphaBRAIN” to select specific unicorn properties — zeroing in on the best available opportunities in the market. The software quickly evaluates thousands of property listings based on 25+ factors, assigning each a reAlphaScore. The score projects how Airbnb-viable the property is, including the projected value in the property market. Through its innovative platform and unique approach, reAlpha is set to secure a leading position for itself and its members in the global short-term rental market. According to Airbnb’s recent IPO filing, the global short-term rental market is valued at $1.2 trillion. The global vacation rental segment is anticipated to expand at a CAGR of 3.4 percent from 2020 to 2027, and reach $113.9 billion in 2027, with millennials being the primary driving force of this growth (https://ibn.fm/jgviA). Research has indicated that 71 percent of those traveling, especially with kids, prefer to cook their meals while traveling, which is a major reason for the vacation rental market boost. For more information, visit the company’s website at www.reAlpha.com. NOTE TO INVESTORS: The latest news and updates relating to reAlpha are available in the company’s newsroom at https://ibn.fm/reAlpha

Date: September 22-24, 2021 Online Livestream Pharma professionals, healthcare providers, influencers, and healthcare-related industries are invited to attend DGE’s 7th Advancing Women’s Leadership Skills & Opportunities in Pharma & Healthcare being held on September 22-24, 2021, as a live online event. The event is organized by Dynamic Global Events (“DGE”), a Life Science leader in hosting B2B events. This global event company caters to the dynamic informational and networking needs of the Pharmaceutical, Biotechnology, Healthcare, Medical Devices, and allied industries.  Women executives in the pharma and healthcare sector face numerous hurdles to reach the echelon of success. The event will feature such inspiring success stories that educate the next generation of leaders. The conference aims to educate, inform, and empower women in leadership roles to bridge the gender disparity gaps in the industry. The live streaming event platform will serve as a vast learning ground for aspiring women medical and healthcare professionals about managing their roles as a leader, dealing with work obstacles and getting the most out of their team. The event will feature eminent speakers and dignitaries who have steadily paved their way up using their leadership skills in the medical industry. These power-packed sessions will assist new medical professionals in enhancing their skills for greater boost their career growth. The opening day of the conference will feature a keynote session by Jeffery Tobias Halter, President of YWOMEN, Gender Strategist, about his book, WHY WOMEN – The Leadership Imperative to Advancing Women and Engaging Men. In this session, he will discuss the tools and steps that should be taken for the long-term advancement of women. While the program pivots around advancing women, it will also explore other factors of diversity including race, age and gender non-binary. The session will discuss ways to create an Integrated Women’s Leadership Strategy designed for growth and enhanced company reputation. They will further examine steps to engage men as allies and advocates for women leadership. Other industry sharing topics of the conference include

• Learning from the best women leaders
• Getting visibility and great work opportunities in the virtual workplace
• Resurrecting and realigning your workplace activities post the pandemic
• Attaining your leadership role and getting a seat on the board of director

To know more about the event, please visit https://ibn.fm/BSuZC

• AnPac Bio-Medical Science Co., Ltd. has developed its proprietary Cancer Differentiation Analysis (“CDA”) technology to detect biophysical signals as an alternative early disease indicator to blood-based biomarker testing for cancer
• The company has laboratories and R&D facilities in China equipped for CDA testing and cancer biochemical testing, as well as a CLIA/CAP accredited laboratory in the United States
• AnPac Bio recently held its 2021 technical symposium in China where KOLs from major hospitals and universities discussed new technologies for cancer detection and treatment.

AnPac Bio-Medical Science (NASDAQ: ANPC) is moving forward with testing and registration of its multi-cancer screening technology in its drive toward commercialization of its proprietary CDA device for a variety of conditions, with the filing of a record 11 types of cancers for assisting in diagnosis in a formal medical device product registration testing application with NMPA. AnPac Bio’s pioneering CDA technology has already produced annual revenues from cancer risk assessment tests for multiple cancers in general population. In 2020, significant growth was achieved with revenues of $3.2 million, according to a Prospectus Supplement filed with the U.S. Securities and Exchange Commission last month (https://ibn.fm/Me4Tk). The current filing announced August 23rd, with China’s National Medical Products Administration (“NMPA”) seeks to expand the usage of CDA technology-based cancer risk testing into hospitals. The 11 cancers which are tumors of the lung, esophagus, stomach, rectum, colon, liver, breast, cervix, thyroid, pancreas and brain, includes  three types of tumors (esophageal cancer, thyroid cancer and brain tumor) that do not yet have generally accepted blood-based biomarkers to be detected with simple blood tests, according to a recent news release about Anpac Bio’s NMPA filing (https://ibn.fm/ot65X). AnPac Bio’s early-detection CDA technology utilizes a biophysical approach which includes acoustical, electrical, magnetic, nano-mechanical and optical environment properties in the blood to determine the risk of more than two dozen cancers. The CDA technology and the company’s proprietary algorithm “measure and analyze these signals at multiple biological levels (including the protein, cellular and molecular levels) and with multiple parameters” that include Protein Tumor Factor and Cellular Tumor Factor data as well as an “overall CDA value,” according to last month’s SEC filing. AnPac Bio’s NMPA filing this month builds on extensive evaluation and successful preclinical trials completed through July, 2021, with the aim of beginning clinical trials at multiple hospitals next year following completion of registration testing with the NMPA. On Aug. 6, AnPac Bio held its 2021 technical symposium in Shanghai with representatives from global fortune 500 companies, life science companies, major hospitals and leading medical schools in attendance, as well as investors and shareholders. The symposium focused on cutting-edge theories, technologies and methods relating to cancer treatment and prevention. The presentations included hospitals’ evaluations of the CDA technology in clinical trials carried out earlier this year, as well as newly un-blinded and analyzed clinical trial data. Fudan University-affiliated Shanghai Tumor hospital, Changhai Hospital and Jiaotong University School of Medicine reported that CDA technology performed well in distinguishing between the healthy and cancer patient groups. They concluded that the CDA technology, its simplicity, high sensitivity and specificity, is an excellent technology for detecting a variety of cancers early, and in particular for early detection of lung and thyroid cancers. For more information, visit the company’s website at www.AnPacBio.com. NOTE TO INVESTORS: The latest news and updates relating to ANPC are available in the company’s newsroom at https://ibn.fm/ANPC

• Flora Growth business divisions include pharmaceuticals, cosmetics, hemp textiles, and food & beverage sectors
• Flora Lab now has three GMP certifications – one each for cosmetics, phytotherapeutic products, and dietary supplements
• Flora Growth operates internationally but has its cultivation and processing operations based in Colombia – with one of the largest outdoor cultivation facilities in the world, aiming to produce medical-grade cannabis flower and derivative products at below-market pricing
• Proposed acquisitions of Vessel Brand and Koch & Gsell, as well as investment into Hoshi International, will help expand the business across international borders and into the US, Europe, and Asia

An internationally focused cannabis CPG company that leverages natural and cost-effective cultivation practices to supply cannabis flower and derivatives to its diverse business divisions, Flora Growth (NASDAQ: FLGC) operates in the pharmaceutical, cosmetics, hemp textiles, and food & beverage sectors. By focusing and prioritizing natural ingredients and sustainability across the value chain of its entire business portfolio, the company is making mindful, premium products to help consumers restore and thrive around the globe. Additionally, Flora Growth operates one of the largest outdoor cultivation facilities in the world, where it produces medical-grade cannabis flower and derivative products at below-market pricing. After completing the first traditional cannabis IPO on NASDAQ without a SPAC, reverse merger, or a dual listing in May 2021, the company is currently seeking revenue-generating acquisitions and strategic partnerships that offer a larger distribution network, amplify revenue growth, and complement its human capital. Each brand in its current portfolio is in line with the company’s mission to be innovative while prioritizing natural ingredients and value-chain sustainability.

• Flora Lab S.A.S – Flora Lab is a GMP-certified manufacturing and R&D center focused on producing pharmaceuticals, cosmetics, and nutraceuticals for domestic and international markets. Thanks to Flora Lab, Flora Growth has a relationship with 2,500+ distribution channels, manufactures 63+ OTC products registered with INVIMA (Colombia National Food and Drug Surveillance Institute), and holds three GMP certificates.
• Flora Beauty – Flora Beauty is Flora Growth’s CBD beauty and cosmetics division founded by fashion and beauty industry icon Paulina Vega. There are currently two CBD-focused skincare brands targeting the United States and the Latin American market – MIND NATURALS and Ô (“AWE”). These products are currently offered globally through e-commerce and the 111 Falabella’s stores located throughout Latin America.
• KASA Wholefoods – KASA Wholefoods is a Colombian manufacturer of food and beverages leveraging responsibly sourced exotic fruits from Amazon. KASA has a distribution agreement anticipated to be worth over $10 million with Tropi, Colombia’s largest food distributor.
• Hemp Textiles & Co. – Through the hemp textiles division, Flora Growth intends to utilize its cultivation and processing infrastructure to capture market share in the rapidly growing hemp industrial segment. Its first brand, Stardog Loungewear, is a line of comfortable loungewear made from natural, organic materials.

In recent months, Flora has announced three major transactions – Vessel Brand, Koch & Gsell, and Hoshi International. The acquisition of Vessel Brand is expected to expand Flora’s premium brand and product portfolio by adding an industry leader in luxury cannabis consumer technology hardware and accessories, while also further diversifying Flora’s global distribution channels, and adding key human capital. Koch & Gsell provides a distribution network of 2,500+ stores to introduce Flora Growth’s products to the Swiss, European, and Asian markets. The acquisition promises to bring patented hemp cigarette manufacturing technology into new markets using Flora Growth’s quality cannabis. The investment into Hoshi International opens a gateway for Flora Growth’s cannabis products through international distribution agreements in the EU and the UK. Hoshi’s experienced team and increased access to the EU cannabis market serve as a catalyst for revenue growth. In a recent news release, Flora Growth announced that its Flora Lab division has received authorization from the Colombian National Food and Drug Surveillance Institute (FDA equivalent) to be a Good Manufacturing Practices (“GMP”) certified manufacturer for cosmetic products (https://ibn.fm/0IHUz). The company now has three GMP certifications – for cosmetics, phytotherapeutics, and dietary supplements. For more information, visit the company’s website at www.FloraGrowth.ca. NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC

• FuelPositive Corp. is a Canadian-based clean energy solutions innovator developing a means of using green ammonia as a non-carbon polluting fuel
• The company was recently featured in a broadcast by NetworkNewsAudio (“NNA”) that highlights FuelPositive’s advances in making green ammonia more portable, more cost-efficient and ultimately more power generating than environmentalist darling hydrogen
• The broadcast notes that traditional ammonia production typically creates significant pollution, but that the key advantage of FuelPositive’s Phase 2 Hydrogen-Ammonia Synthesizer is that it eliminates the pollution factor and makes carbon free ammonia easy to produce where needed as a transportation fuel
• The broadcast highlights the results of FuelPositive’s decision to commission a study of Canada’s off-peak green electricity capacity, showing that the country has sufficient energy to utilize green ammonia as a carbon-free fuel for all of Canada’s passenger and commercial freight needs

The dedication of Canadian-based FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF) toward building renewable energy technology through manufacturing, licensing, partnership and acquisition opportunities, is the focus of a recent audio broadcast featuring news about FuelPositive’s decision to commission an analysis of Canada’s green off-peak electricity capacity, measuring the Canadian transportation sector’s fuel needs and carbon emissions. The NNA broadcast notes that ammonia produced in a carbon-free manner can provide fuel for commercial and public transportation and do it in a way that promotes responsible climate policy. “Many people don’t know it, but planes, trains, ships, trucks and other vehicles can be converted to run on ammonia – just as easily as they can be converted from gasoline and diesel to run on propane”, FuelPositive CEO Ian Clifford states in the news release about the broadcast (https://ibn.fm/FEOjZ). “The transportation sector just didn’t see a benefit to switching to ammonia until now, because the production of traditional ammonia results in massive carbon emissions. But, when you use our carbon-free NH3 made from green electricity rather than traditional ammonia, it means we can move people around and transport goods with no pollution.” In addition, ammonia presents advantages over the generally preferred green energy solutions that rely on hydrogen. Hydrogen can be stored physically as either a gas or a liquid, however the storage and transportation process is complicated because such storage typically requires high-pressure tanks and cryogenic temperatures. Therefore, improvements in the technology necessary to store and transport hydrogen are generally considered key to advancing its use as a renewable solution (https://ibn.fm/om7zd). Ammonia, however, is easy to store and transport using existing infrastructure. Its chemical symbol, NH3, is often referred to as hydrogen nitride instead of ammonia in recognition of its nitrogen and three hydrogen atoms. That structure makes ammonia the ideal carrier for hydrogen — in addition to the portability of FuelPositive’s technology, the end user can convert the green ammonia back to its hydrogen element to be used to produce electricity in a hydrogen fuel cell. It’s also much less expensive to manufacture carbon free ammonia than pure hydrogen by volume, according to the company. FuelPositive’s carbon-free production process also eliminates fertilizer-related carbon emissions in the agriculture sector. Currently, the agriculture industry remains the largest user of ammonia. Over 80 percent of traditional ammonia is used as fertilizer. The analysis by emissions reduction and carbon credit specialist Andre Mech that FuelPositive commissioned found that Canada has enough off-peak green electricity to produce carbon free ammonia to fuel 63 percent of all the passenger cars, light trucks, passenger aviation, buses, light rail, motorcycles, freight trucking, freight aviation, rail, marine and other sector vehicles in the country using non-polluting, carbon-free NH3 as a fuel. The analysis also found that Canada has enough off-peak green electricity to produce carbon free ammonia to fuel 100 percent of the passenger and commercial freight needs of its industries. For more information, visit the company’s website at www.FuelPositive.com. NOTE TO INVESTORS: The latest news and updates relating to NHHHF are available in the company’s newsroom at https://ibn.fm/NHHHF

• Fan Pass releases new offering exclusively for independent artists seeking next-level advantage in analytics, exposure, merchandise sales and overall streaming revenue
• The Company’s Pro services offer artists the opportunity to gain access to basic, standard, and premium logo, merchandise, and marketing services for a fee
• Streaming gear is available for purchase for artists on the platform to further enhance their craft using high quality equipment
• Fans can sign up to gain access to their favorite artists for a monthly fee – offering VIP access to live stream events and behind-the-scenes access

Currently at the heart of its 120-day plan, Friendable (OTC: FDBL), a mobile technology and marketing company focused on developing and identifying products, services, and brand opportunities, is increasing its offering to artists joining the Fan Pass platform with pro services and streaming merchandise. Artists can sign up for the livestreaming platform for free, host live performances for fans, and earn revenue for the sales they gain on the platform. With the release of the Fan Pass version 2.0 and the Artist Pro offering being tested for independent artists using the platform, CEO Robert A Rositano, Jr. stated “As we are onboarding new artists to the Fan Pass version 2.0 platform, it’s the ideal time to deliver additional support services to any artist who feels big labels aren’t for them and who wants to find an alternative way to get heard, get known and get paid. Delivering this capability to the artists on our platform is what Fan Pass is all about” (https://ibn.fm/FhiEV). The current selection of streaming gear is available through the Fan Pass store online. Equipment available online includes amplifiers, tripods, wireless microphones, and other high-quality items that every artist joining the platform needs to perfect their art. Those who sign up for the newsletter will receive an additional discount with their first purchase. Artists can use their new gear to make the best quality music videos and live streamed events to increase revenue potential. The user feedback from the Artist Pro structure will provide Friendable with more forward-thinking marketing strategies, which is aimed toward providing users with:

• The activation and set up of a merchandise store
• Custom merchandise designs (includes initial merchandise design)
• VIP all-access subscription to Fan Pass platform and content
• Promotion of all scheduled artist events
• Advanced analytics and fan data access, reported directly through the artist’s dashboard

This is available for the low rate of $8.99 per month. Along with the streaming gear, Friendable offers a premium line of pro services to help advance artists and their careers. These pro services include logo, merchandise, and marketing categories – in basic, standard, and premium formats. Each category provides artists access to quality logos, merchandise, and marketing materials made for their music and brand. Artists also make revenue on the merchandise they sell through the Fan Pass store. These are all a part of the digital media campaign being rolled out for artist and fan acquisitions by the company. The goal is to show artists, and fans alike, that the brand is one that can be trusted as a long-term partner while still extending the reach for new revenue growth opportunities. The Artist Pro platform is just one of the ways that Friendable is delivering their commitment to artists and fans in a tangible way, as pointed out by Rositano Jr. in an interview. He also pointed out that it is through these new offerings on the platform that the company is able to share achievements with artists, fans, the Friendable team, and its shareholders. For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com. NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL

• New Sagitta electric vehicle will be unveiled at Nov. 17 LA Auto Show
• Imperium is CMW’s primary Sagitta distribution partner; company anticipates high demand for game-changing vehicle
• Limited production planned by late 2022, reservations accepted mid-year

DSG Global (OTCQB: DSGT) and its subsidiary, Imperium Motors, have announced the planned unveiling of the Sagitta(TM) electric vehicle during the upcoming Nov. 17, 2021, LA Auto Show (https://ibn.fm/3R6GE). Imperium will partner with California Mobility Works (“CMW”) to show the new three-wheel, four-passenger EV, which is expected to create quite a stir during the shows. “We are thrilled to team up with CMW and make Sagitta a huge success,” said Rick Curtis of Imperium Motors. “As a company focused on the EV market for many years, we are very confident that this vehicle will be a big winner.” Imperium is CMW’s primary Sagitta distribution partner, and the company anticipates high demand for the vehicle as well as a need for downstream partners to meet that demand. The innovative vehicle features superb styling and engineering and is designed to set a new standard for aesthetics, passenger and cargo space, range, and value. Sagitta will also showcase new technology that allows easy configurability and a wide range of owner-defined interior features. In addition, the vehicle should dramatically expand the accessibility of environmentally responsible EV technology to a broad range of consumers. “I am very excited to roll out this incredible new vehicle, which is not only a breakthrough in value for the EV market, but it is a thing of beauty and people will be pleasantly surprised by many innovations in the design,” said CMW cofounder and chief designer Jim Shook. Following the Nov. 17 unveiling of the Sagitta, CMW will begin initial testing and validation of the vehicle. The company anticipates limited production by late 2022 and will start accepting reservations for the vehicle sometime next year. “Jim and his team have done a remarkable job with Sagitta, which by the way means arrow in Latin,” said CMW chair Scott Burton. “And as an EV enthusiast, I am totally confident in the product and the immediate and continued success it will have in the market.” Founded in 2018 with the main objective of designing and manufacturing EVs, CMW is focused on transforming the EV market by providing world-class electric vehicles specifically designed to expand and accelerate the already fast-growing space. With an end goal of becoming a leading EV company within five years, CMW is committed to delivering superior value without sacrificing style, performance or safety. The company was founded by several luminaries of Silicon Valley including Kamal Consaga, Bobby Rekhi and Jim Shook. Imperium Motor Company is an ideal partner for CMW. An expert in EV sales, marketing and distribution, Imperium offers an impressive array of EV vehicles with emphasis on great design, a green mindset, performance, and functionality. Imperium vehicles include high-speed, mid-speed and low-speed electric vehicles, including cars, trucks, SUVs, vans, e-bikes, buses and scooters. “The addition of CMW to IMC’s list of OEM partners is a win-win scenario,” the company stated, “as it will greatly strengthen IMC’s product offering, while IMC represents a ready-made distribution and service organization for CMW-designed products.” DSG Global is an emerging global technology company with an array of interconnecting businesses in some of the fastest-growing market sectors. With roots in the golf industry, in which it specializes in fleet management with patented analytics, mobile touch-screen engagement and electric golf carts under the Vantage Tag Systems (“VTS”) brand, the company is moving quickly with road-ready electric vehicles sold through its Imperium Motor Company subsidiary. For more information, visit the company’s website www.DSGTGlobal.com. NOTE TO INVESTORS: The latest news and updates relating to DSGT are available in the company’s newsroom at https://ibn.fm/DSGT